Eli Lilly
Sentiment Over Time
Analysis Timeline
"Stock dropped after HSBC downgrade due to doubts about the market size for weight-loss drugs."
"Stock tripled in 2-3 years, successfully gaining market share in weight-loss drugs with strong products, though its P/E of 740 suggests significant overvaluation."
"Gaining market share from Novo Nordisk in the US GLP1 market."
"Stock gained significantly after a competitor's experimental weight-loss drug failed to outperform its own product."
"Stock was up about 5% after a competitor's weight-loss drug showed less effectiveness in a study."
"Used as an example of a pharmaceutical company exploring AI applications in medicine (Lily Direct), illustrating the potential for AI in healthcare despite regulatory challenges."
"Mentioned as a 'crowded long' stock, no specific sentiment."
"Mentioned as a competitor to Novo Nordisk, presenting strong financial figures."
"Identified as a significant competitor to Novo Nordisk in the weight loss market, described as having a 'better sales apparatus'."
"Strong growth in the weight-loss sector, exceeding expectations, indicating strong market demand for similar products."
"Benefits from reduced competition in the GLP-1 market due to FDA action against knockoff versions."
"Stock increased almost 5% in conjunction with Novo Nordisk, benefiting from the FDA's action against GLP-1 imitators."
"Positioned as a strong competitor gaining market share from Novo Nordisk in the pharmaceutical sector, particularly in weight-loss drugs."
"Delivered strong Q4 results, driven by obesity and diabetes blockbusters, but its valuation is perceived as very high and over-optimistic."
"Stock rose significantly on positive news and anticipation for a new diet pill, signaling strong market confidence."
"Stock dropped almost 10%, likely due to competitive pressures in the weight-loss drug market, similar to Novo Nordisk."
"Delivered strong quarterly results, stock surged 11%, entered the 'Billion Dollar Club,' showing superior efficacy and market penetration in weight-loss drugs."
"Strong financial performance, robust outlook, and increased market share in a key segment (weight-loss drugs)."
"Sales of Zetbound and Mounjaro more than doubled in the fourth quarter, and the company is preparing to launch a new weight loss pill that analysts predict could be a hit, leading to a share jump of over 10%."
"Achieved record results, significant revenue growth, landmark market cap, and strong sales of key GLP-1 drugs, with a promising next-generation product."
"Driving intense competition and reshaping the GLP-1 drug market, putting pressure on competitors."
"Negatively affected by competitor Novo Nordisk's lowered forecast, indicating potential broader market concerns."
"Strong performance driven by weight loss drugs (GLP-1s), expected to beat earnings and possibly raise guidance."
"Strong market performance with a more effective GLP-1 drug (Tirzepatide), gaining market share due to better product and commercial strategy."
"Erwähnt im Zusammenhang mit Adipositas-Medikamenten, die das Geschäft der Adipositas-Chirurgie beeinflussen."
"Negativ betroffen von Trumps Ankündigung, dass Amerikaner nicht mehr für Medikamente zahlen sollen als Europäer."
"Kooperiert mit Nvidia, um ein gemeinsames KI-Labor für die Medikamentenentwicklung zu gründen."
"Die Zulassung ihrer Abnehmpille verzögerte sich, was indirekt positiv für Novo Nordisk ist, aber nicht direkt negativ für das Unternehmen selbst."
"Verzögerung der Zulassung ihres Abnehmmedikaments um mehrere Monate, was einen Wettbewerbsnachteil gegenüber Novo Nordisk bedeutet."